Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NAV4694: Phase III started

Navidea began an open-label, U.S. Phase III trial to evaluate a single

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE